Narcotic Antagonists

"Narcotic Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents inhibiting the effect of narcotics on the central nervous system.

Descriptor ID	D009292
MeSH Number(s)	D27.505.696.543 D27.505.696.663.850.512 D27.505.954.427.550
Concept/Terms	Narcotic Antagonists Narcotic Antagonists Antagonists, Narcotic Opioid Receptor Antagonists Antagonists, Opioid Receptor Receptor Antagonists, Opioid Opioid Antagonists Antagonists, Opioid Competitive Opioid Antagonists Competitive Opioid Antagonists Antagonists, Competitive Opioid Opioid Antagonists, Competitive

Below are MeSH descriptors whose meaning is more general than "Narcotic Antagonists".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Narcotic Antagonists [D27.505.696.543]
Peripheral Nervous System Agents [D27.505.696.663]
Sensory System Agents [D27.505.696.663.850]
Narcotic Antagonists [D27.505.696.663.850.512]
Therapeutic Uses [D27.505.954]
Central Nervous System Agents [D27.505.954.427]
Narcotic Antagonists [D27.505.954.427.550]

Below are MeSH descriptors whose meaning is related to "Narcotic Antagonists".

Below are MeSH descriptors whose meaning is more specific than "Narcotic Antagonists".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Narcotic Antagonists" by people in this website by year, and whether "Narcotic Antagonists" was a major or minor topic of these publications.

Bar chart showing 43 publications over 20 distinct years, with a maximum of 4 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	1	0	1
2003	1	1	2
2004	1	2	3
2005	3	0	3
2006	0	1	1
2008	4	0	4
2009	2	0	2
2010	1	2	3
2011	0	2	2
2014	1	0	1
2016	1	2	3
2017	1	0	1
2018	2	0	2
2019	1	0	1
2020	1	2	3
2021	1	2	3
2022	0	1	1
2023	0	2	2
2024	1	2	3
2025	1	1	2

Below are the most recent publications written about "Narcotic Antagonists" by people in Profiles.

Cowan E, O'Brien-Lambert C, Eiting E, Bull E, Ryder J, Calderon Y, Salsitz E. Emergency department-initiated oral naltrexone for patients with moderate to severe alcohol use disorder: A pilot feasibility study. Acad Emerg Med. 2025 05; 32(5):488-497.

View in: PubMed
Quintanilla ME, Israel Y. Role of Metabolism on?Alcohol Preference, Addiction, and Treatment. Curr Top Behav Neurosci. 2025; 71:193-216.

View in: PubMed
Roth E, Bingaman A, Stern S, McKeever R, D'Orazio J, Schlosser SP, Cheng K, Zhao H, Anderson JH. Buprenorphine Induction in Trauma Patients With Opioid Use Disorder - A Single Center Experience? J Surg Res. 2024 09; 301:686-695.

View in: PubMed
Noverati N, Mehta S, Reed MK, Zavodnick J. Understanding Barriers and Assessing Education Intervention on Prescribing Naltrexone for Alcohol Use Disorder. Am J Med Qual. 2024 Jul-Aug 01; 39(4):197-198.

View in: PubMed
Perrone J, Haroz R, D'Orazio J, Gianotti G, Love J, Salzman M, Lowenstein M, Thakrar A, Klipp S, Rae L, Reed MK, Sisco E, Wightman R, Nelson LS. National Institute on Drug Abuse Clinical Trials Network Meeting Report: Managing Patients Exposed to Xylazine-Adulterated Opioids in Emergency, Hospital and Addiction Care Settings. Ann Emerg Med. 2024 07; 84(1):20-28.

View in: PubMed
Quintanilla ME, Morales P, Santapau D, ?vila A, Ponce C, Berrios-C?rcamo P, Olivares B, Gallardo J, Ezquer M, Herrera-Marschitz M, Israel Y, Ezquer F. Chronic Voluntary Morphine Intake Is Associated with Changes in Brain Structures Involved in Drug Dependence in a Rat Model of Polydrug Use. Int J Mol Sci. 2023 Dec 03; 24(23).

View in: PubMed
Quezada M, Ponce C, Berr?os-C?rcamo P, Santapau D, Gallardo J, De Gregorio C, Quintanilla ME, Morales P, Ezquer M, Herrera-Marschitz M, Israel Y, Andr?s-Herrera P, Hip?lito L, Ezquer F. Amelioration of morphine withdrawal syndrome by systemic and intranasal administration of mesenchymal stem cell-derived secretome in preclinical models of morphine dependence. CNS Neurosci Ther. 2024 04; 30(4):e14517.

View in: PubMed
Khatri UG, Lee K, Lin T, D'Orazio JL, Patel MS, Shofer FS, Perrone J. A Brief Educational Intervention to Increase ED Initiation of Buprenorphine for Opioid Use Disorder (OUD). J Med Toxicol. 2022 07; 18(3):205-213.

View in: PubMed
Eudy-Byrne R, Zane N, Adeniyi-Jones SC, Gastonguay MR, Ruiz-Garcia A, Kaushal G, Kraft WK. Pharmacometric dose optimization of buprenorphine in neonatal opioid withdrawal syndrome. Clin Transl Sci. 2021 11; 14(6):2171-2183.

View in: PubMed
Alexander K, Pogorzelska-Maziarz M, Gerolamo A, Hassen N, Kelly EL, Rising KL. The impact of COVID-19 on healthcare delivery for people who use opioids: a scoping review. Subst Abuse Treat Prev Policy. 2021 08 09; 16(1):60.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement